Published in Eur Radiol on February 26, 2012
Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. Eur Radiol (2015) 0.80
Detection of invasive components in cases of breast ductal carcinoma in situ on biopsy by using apparent diffusion coefficient MR parameters. Eur Radiol (2013) 0.80
Diffusion-tensor imaging as an adjunct to dynamic contrast-enhanced MRI for improved accuracy of differential diagnosis between breast ductal carcinoma in situ and invasive breast carcinoma. Chin J Cancer Res (2015) 0.78
MRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: correlation of MRI with histology. NMR Biomed (2015) 0.75
ROC methodology in radiologic imaging. Invest Radiol (1986) 7.55
Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology (1999) 6.50
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet (2007) 5.63
Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology (2004) 5.37
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst (2010) 2.80
Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst (2004) 2.72
Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg (2009) 2.18
Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J (2005) 2.04
Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg (2008) 1.67
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology (2011) 1.59
Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology (2001) 1.40
Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology (2007) 1.39
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer (1982) 1.25
Stereotaxic 14-gauge breast biopsy: how many core biopsy specimens are needed? Radiology (1994) 1.23
Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg (2008) 1.20
High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol (2003) 1.19
Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev (2008) 1.15
Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol (2007) 1.11
Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol (2003) 1.10
Current management of DCIS: a review. Breast Cancer Res Treat (2007) 1.07
The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma. Am J Surg (2006) 1.02
Stereotactic 11-gauge vacuum-assisted breast biopsy: influence of number of specimens on diagnostic accuracy. Radiology (2004) 1.02
Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR Am J Roentgenol (2006) 1.02
Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat (2006) 1.01
Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol (2007) 0.99
Characterization of ductal carcinoma in situ on diffusion weighted breast MRI. Eur Radiol (2011) 0.98
Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis. Breast Cancer Res Treat (2011) 0.97
Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol (2008) 0.94
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg (2008) 0.94
Comparison of MRI features of different grades of DCIS and invasive carcinoma of the breast. JBR-BTR (2005) 0.94
Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease? Magn Reson Imaging (2005) 0.94
Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation. Radiographics (2010) 0.92
Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg (2007) 0.92
Accuracy of 11-gauge vacuum-assisted core biopsy of mammographic breast lesions. Ann Surg Oncol (2003) 0.90
MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component. Eur J Radiol (2007) 0.89
Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol (2008) 0.87
Characteristics of ductal carcinoma in situ in magnetic resonance imaging. Clin Imaging (2007) 0.86
The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. Int J Clin Pract (2008) 0.86
Radiography of microcalcifications in stereotaxic mammary core biopsy specimens. Radiology (1994) 0.85
Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: is it justified? J Clin Pathol (2009) 0.80
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol (2008) 2.49
Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol (2011) 2.42
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging (2010) 2.32
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg (2015) 2.30
Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol (2013) 2.08
Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol (2006) 1.95
Breast tomosynthesis in clinical practice: initial results. Eur Radiol (2009) 1.89
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) 1.84
Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol (2009) 1.71
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol (2011) 1.59
Tumour thickness in oral cancer using an intra-oral ultrasound probe. Eur Radiol (2010) 1.58
Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One (2011) 1.56
Lymphatic drainage patterns from the breast. Ann Surg (2004) 1.53
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2014) 1.49
A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Res Treat (2010) 1.47
[Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial]. Ned Tijdschr Geneeskd (2015) 1.45
Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. J Surg Oncol (2006) 1.43
Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment. J Thorac Oncol (2009) 1.41
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat (2009) 1.37
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol (2012) 1.28
Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med (2005) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol (2003) 1.20
The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer (2007) 1.20
Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun (2011) 1.20
Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol (2008) 1.20
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer (2012) 1.18
Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis. Eur J Cancer (2005) 1.18
Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech (2011) 1.16
Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol (2003) 1.14
Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol (2007) 1.11
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol (2010) 1.11
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat (2010) 1.07
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res (2012) 1.07
The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med (2007) 1.06
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer (2011) 1.06
Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer (2010) 1.06
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat (2010) 1.05
MR-guided high-intensity focused ultrasound ablation of breast cancer with a dedicated breast platform. Cardiovasc Intervent Radiol (2012) 1.03
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res (2011) 1.03
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res (2014) 1.03
Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. Ann Surg Oncol (2007) 1.03
Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600 nm: comparison of classification methods. J Biomed Opt (2011) 1.02
Radioactive seed localization of breast lesions: an adequate localization method without seed migration. Breast J (2011) 1.01
A prospective assessment of surgical risk factors in 400 cases of skin-sparing mastectomy and immediate breast reconstruction with implants to establish selection criteria. Plast Reconstr Surg (2007) 1.01
Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat (2015) 1.01
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat (2011) 1.00
Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer (2006) 1.00
A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. BMC Genomics (2013) 1.00
MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg (2010) 0.99
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res (2014) 0.99
Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol (2009) 0.98
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res (2014) 0.97
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast (2013) 0.97
Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics (2009) 0.97
Precise correlation between MRI and histopathology - exploring treatment margins for MRI-guided localized breast cancer therapy. Radiother Oncol (2010) 0.96
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest (2002) 0.96
Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int (2005) 0.96
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat (2010) 0.95
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics (2011) 0.93
Clinically and mammographically occult breast lesions on MR images: potential effect of computerized assessment on clinical reading. Radiology (2005) 0.93
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat (2012) 0.92
Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients. Eur Radiol (2005) 0.92
HER2 gene amplification in patients with breast cancer with equivocal IHC results. J Clin Pathol (2011) 0.91
Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 0.91
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg (2010) 0.90
Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis. J Surg Oncol (2014) 0.90
Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat (2012) 0.89